CME Presentations
2022 ASPC Hot Topic Series
Presentations
Considerations for Heart Failure Management in the African American Population
Duration: 60 minutes
Presented on: January 5, 2022
ACC Expert Consensus Decision Pathway for Bleeding Management: Applications in Patients on Oral Anticoagulants and Cost Implications
Duration: 60 minutes
Presented on: February 9, 2022
Evaluating the Evidence: GLP1 Receptor Agonists Improve Cardiovascular Measures in Patients with Diabetes
Duration: 60 minutes
Presented on: June 21, 2022
Reducing Mortality and Hospitalization in Heart Failure: New Guidelines and New and Emerging Treatments for HFpEF and HFrEF
Duration: 60 minutes
Presented on: November 15, 2022
Speakers
Martha Gulati, MD, MS, FACC, FAHA, FASPC, FESC
Martha Gulati, MD, MS, FACC, FAHA, FASPC, FESC
President - American Society for Preventive Cardiology
Martha Gulati, MD, MS, FACC, FAHA, FASPC, FESC is the President of the American Society for Preventive Cardiology. She was a Professor of Medicine and the inaugural Chief of Cardiology at the University of Arizona and the inaugural Sarah Ross Soter Chair in Women’s Cardiovascular Health. Dr. Gulati was also the Section Director for Women’s Cardiovascular Health and Preventive Cardiology at The Ohio State University. She is the author of the best-seller, “Saving Women’s Hearts”, and she serves as the chair of the national chest pain guidelines. Furthermore, Dr. Gulati is the principal investigator of the St. James Women Take Heart Project, a study examining cardiac risk factors in women, which set standards for women’s fitness levels and heart rate response to exercise in women.
Nasrien E. Ibrahim, MD, FACC, FHFSA
Nasrien E. Ibrahim, MD, FACC, FHFSA
Associate Program Director, cardiology fellowship program
Nasrien Ibrahim, MD, FACC, FHFSA, was faculty at the Massachusetts General Hospital/Harvard Medical School before becoming the Associate Program Director of the cardiology fellowship program at Inova Heart and Vascular Institute. Dr. Ibrahim is a book author and an interim associate editor for the Journal of the American College of Cardiology: Heart Failure. Her research interests include biomarkers, improving adherence to guideline-directed therapies in heart failure patients, understanding mechanisms of disparities in the care of underserved populations, and improving access to heart transplant in historically excluded populations. Dr. Ibrahim was invited by the White House Office of Public Engagement to participate in a Health Equity Leaders Roundtable Series focused on access to care.
Clyde Yancy, MD, MSc
Clyde Yancy, MD, MSc
Chief, Division of Medicine-Cardiology
Tyler Gluckman, MD, FACC, FAHA
Tyler Gluckman, MD, FACC, FAHA
Medical Director
Ty Gluckman, MD, FACC, FAHA is the Medical Director of the Center for Cardiovascular Analytics, Research, and Data Science (CARDS) at the Providence Heart Institute in Portland, Oregon and an adjunct faculty member of the Ciccarone Center for the Prevention of Heart Disease at The Johns Hopkins Hospital in Baltimore, Maryland. Dr. Gluckman is Associate Editor for Guidelines and Clinical Documents for ACC.org. His principal clinical interests include identifying, coordinating, and implementing cardiovascular care improvement strategies. Dr. Gluckman has authored or co-authored over 100 scientific articles, reviews, and book chapters. He was lead developer for the American College of Cardiology (ACC) Atherosclerotic Cardiovascular Disease Risk Estimator app, the best medical app in 2014.
Deepak Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
Deepak Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
Executive Director of Interventional Cardiovascular Programs
Deepak Bhatt MD, MPH, FACC, FAHA, FSCAI, FESC, is the Executive Director of Interventional Cardiovascular Programs at Brigham and Women’s Hospital and Professor of Medicine at Harvard Medical School. Dr. Bhatt received the Eugene Braunwald Teaching Award for Excellence in the Teaching of Clinical Cardiology from Brigham and Women’s Hospital in 2017, ACC’s Distinguished Mentor Award in 2018, AHA’s Distinguished Scientist Award in 2019, and NLA’s Honorary Lifetime Membership Award in 2021. He has authored or co-authored over 1800 publications and has been listed by the Web of Science Group as a Highly Cited Researcher from 2014 to 2021. Dr. Bhatt is the Editor of the peer-reviewed Journal of Invasive Cardiology and Editor-in-Chief of the Harvard Heart Letter for patients.
Keith Ferdinand, MD, FACC, FAHA , FNLA, FASCP
Keith Ferdinand, MD, FACC, FAHA , FNLA, FASCP
Professor of Clinical Medicine
Keith Ferdinand, MD, FACC, FAHA, FNLA, FASCP, is currently a Professor of Clinical Medicine at Tulane Heart and Vascular Institute. Dr. Ferdinand is on the board of the Partnership to Advance Cardiovascular Health, National Lipid Association, and the American Society for Preventive Cardiology. His research is in hypertension lipids, cardiometabolic risk, and cardiovascular disease especially in racial/ethnic minorities. He has participated in numerous clinical education activities in the community, regarding eliminating disparities during the COVID-19 pandemic. Furthermore, as the president of Healthy Heart Community Prevention Project in New Orleans, Dr. Ferdinand has offered community education and advocacy on racial and ethnic disparities before and during the COVID-19 pandemic.
Darren K. McGuire, MD, MHSc
Darren K. McGuire, MD, MHSc
Distinguished Teaching Professor of Medicine
Gregg C. Fonarow, MD, FACC, FAHA, FHFSA
Gregg C. Fonarow, MD, FACC, FAHA, FHFSA
Eliot Corday Professor of Cardiovascular Medicine and Science
Gregg Fonarow, MD, FACC, FAHA, FHFSA, is the Eliot Corday Professor of Cardiovascular Medicine and Science at UCLA. Dr. Fonarow serves as Chief of the UCLA Division of Cardiology (Interim), Director of the Ahmanson-UCLA Cardiomyopathy Center, and Co-Director of UCLA’s Preventative Cardiology Program. His research interests center on acute and chronic heart failure, preventative cardiology, quality of care, outcomes, and implementing treatment systems to improve clinical outcomes. Dr. Fonarow has published over 1400 research studies and clinical trials in heart failure, disease management, preventative cardiology, and outcomes research. He is a member of the Association of University Cardiologists. In 2022, Dr. Fonarow was the recipient of the American Heart Association’s Gold Heart Award.
Scott Soloman, MD
Scott Soloman, MD
Edward D. Frohlich Distinguished Chair, Professor of Medicine
Scott Solomon, MD, is the Edward D. Frohlich Distinguished Chair, Professor of Medicine at Harvard Medical School and Brigham and Women’s Hospital, where he directs the Clinical Trials Outcomes Center and the Cardiac Imaging Core Laboratory. His research interests are on cardiac structure and function following myocardial injury and heart failure, modifiers of risk and outcomes in heart failure, and cardiovascular imaging. Dr. Solomon is a world-renowned clinical trialist, having led many phase 2 and phase 3 clinical trials in heart failure, including the PARAGON-HF and DELIVER trials in heart failure with mildly reduced and preserved ejection fraction. He has published over 950 peer-reviewed articles, three textbooks of echocardiography, and serves as Editor for Braunwald’s Heart Disease.
CME Information
Reducing Mortality and Hospitalization in Heart Failure: New Guidelines and New and Emerging Treatments for HFpEF and HFrEFThis activity is jointly provided by Global Education Group and PlatformQ Health Education, LLCACKNOWLEDGEMENT
This activity is supported by educational grants from Alexion Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC, Merck & Co., Inc., Novo Nordisk Inc., and Novartis Inc.DATE OF RELEASE/EXPIRATION
This activity was released on November 15, 2022 and is valid until November 15, 2023. Requests for credit must be made no later than November 15, 2023.TARGET AUDIENCE
The primary target audiences for the HCP activity are Cardiologists, primary care physicians, nurse practitioners, and physiciansSTATEMENT OF NEED/PROGRAM OVERVIEW
Despite advances in heart failure (HF) treatment over the past decade, the disease is still associated with high costs and high rates of morbidity, hospitalization, and mortality. In 2021, an update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure was published and yet the treatment course remains confusing for many clinicians. Research is also rapidly emerging on novel therapies for both HF with preserved ejection fraction (HFpEF) and HF with reduced ejection fraction (HFrEF), including anti-diabetic agents that have shown cardiovascular benefits.
In this program a panel of expert cardiologists will navigate these guideline-concordant treatment approaches to promote effective care of HF and optimization of pharmacotherapy. Panelists will review the latest updates to the treatment guidelines and the rationales for those changes, along with clinical trial data related to HFpEF and HFrEF. Clinicians will be prepared to address barriers to guideline-directed medical therapy in effort to reduce mortality rates and improve quality of life for their patients with HF.EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:- Explain the rationale for important changes in the 2022 AHA/ACC/HFSA guideline for the management of heart failure
- Identify HF patients who should receive ARNI/ACE/ARB as first line treatment, and those who should receive a SGLT2 inhibitors as part as therapy intensification newer HF agents with efficacy in reducing mortality and hospitalization rates in patients with HF
- Describe the mechanisms of action of newly approved agents for the management of HF and how they relate to HF pathophysiology (ARNI and SGLT2 inhibitors)
- Discuss recent clinical trial data from emerging agents that have demonstrated efficacy in the treatment of HFrEF and HFpEF
PHYSICIAN ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.PHYSICIAN CREDIT DESIGNATION
Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.ESTIMATED TIME TO COMPLETE
This activity should take approximately 60 minutes to complete.INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.FEE INFORMATION & REFUND/CANCELLATION POLICY
There is no fee for this educational activity.DISCLOSURE OF CONFLICTS OF INTEREST
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:Name of Faculty or Presenter Reported Financial Relationship Martha Gulati MD, MS, FACC, FAHA, FASPC, FESC
President-American Society for Preventive Cardiology
Director, Preventive Cardiology
Associate Director, Barbra Streisand Women’s Heart Center
Associate Director, Preventive and Cardiac Rehabilitation Center
Anita Dann Friedman Endowed Chair in Women’s Cardiovascular Medicine & Research
Smidt Heart InstituteNothing to disclose Scott Soloman, MD
Edward D. Frohlich Distinguished Chair, Professor of Medicine
Harvard Medical School
Director of Clinical Trials Outcomes Center and the Cardiac Imaging Core Laboratory
Brigham and Women’s HospitalConsulting Fee (e.g., Advisory Board): Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boeringer-Ingelheim, BMS, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GSK, Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellProThera, Moderna, American Regent, Sarepta, Lexicon, Anacardio, Akros, Puretech Health
Contracted Research: Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, BMS, Celladon, Cytokinetics, Eidos, Gilead, GSK, Ionis, Lilly, Mesoblast, MyoKardia, Neurotronik, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Theracos, US2.AIGregg Fonarow, MD
Eliot Corday Professor of Cardiovascular Medicine and Science
Director, Ahmanson-UCLA Cardiomyopathy Center
Co-Director, UCLA Preventative Cardiology Program
Chief, UCLA Division of Cardiology (Interim)
David Geffen School of Medicine, UCLAConsulting Fee: Abbott, Amgen, AstraZeneca, Cytokinetics Egnite, Janssen, Medtronic, Merck Novartis, Pfizer, Urovant,
Research: NIH
Speakers Bureau: Novartis
The planners and managers have the following relevant financial relationships with ineligible companies:
Name of Planner Reported Financial Relationship Lindsay Borvansky Nothing to disclose Andrea Funk Nothing to disclose Liddy Knight Nothing to disclose Ashley Cann Nothing to disclose Lauren Sinclair Nothing to disclose Carole Drexel Nothing to disclose Colleen Hefner Nothing to disclose Caroline Laurendeau Nothing to disclose DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.DISCLAIMER:
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.CONTACT INFORMATION
Accreditation Support:
For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.comTechnical Support:
For any technical issues or issues with your CME Certificate, please contact CardioCareLive at 877-394-1306 or at Support@CardioCareLive.com .
GLP1 Receptor Agonists Improve Cardiovascular Measures in Patients with DiabetesThis activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with the American Society for Preventive Cardiology (ASPC).ACKNOWLEDGEMENT
This activity is supported by educational grants from Alexion Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC, Merck Sharp & Dohme Corp, and Novo Nordisk Inc.DATE OF RELEASE/EXPIRATION
This activity was released on June 21, 2022 and is valid for 12 months. Requests for credit must be made no later than June 21, 2023.TARGET AUDIENCE
The primary target audiences for the HCP activity are cardiologists and specialty NPs and PAs. The secondary target audiences are endocrinologists and primary care clinicians.STATEMENT OF NEED/PROGRAM OVERVIEW
Of the 415 million people living with diabetes in the world, 90% have type 2 diabetes (T2D), which doubles the risk of major cardiovascular complications. Cardiovascular disease remains the major cause of increased mortality in this patient population.
Initially investigated as glucose-lowering therapies, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have since demonstrated cardiac benefits and are becoming an important part of the cardiologist's armamentarium. Cardiologists are now faced with the challenge of identifying patients who best qualify for this therapeutic approach and selecting treatment in a patient-centric manner. However, a lack of familiarity with these agents may make cardiology clinicians hesitant to integrate these therapies into practice.
Join an esteemed panel of cardiology experts to evaluate the different GLP-1 RA formulations and explore how they differ in terms of documented cardiovascular impacts and weight reduction. Panelists will review the latest guideline recommendations on the management of CV risk in people with T2D and discuss the proper use of GLP-1 RAs in practice, including patient selection.EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:- Differentiate the various GLP-1 RAs based on their documented impact on CV-related markers and weight reduction in addition to their glucose lowering properties
- Apply guideline-based recommendations regarding the use of GLP-1 RA therapy in patients with T2D
PHYSICIAN ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.PHYSICIAN CREDIT DESIGNATION
Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.ESTIMATED TIME TO COMPLETE
This activity should take approximately 60 minutes to complete.INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.FEE INFORMATION & REFUND/CANCELLATION POLICY
There is no fee for this educational activity.DISCLOSURE OF CONFLICTS OF INTEREST
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:Name of Faculty or Presenter Reported Financial Relationship Martha Gulati MD, MS, FACC, FAHA, FASPC, FESC
President-American Society for Preventive Cardiology
Director, Preventive Cardiology
Associate Director, Barbra Streisand Women’s Heart Center
Associate Director, Preventive and Cardiac Rehabilitation Center
Smidt Heart InstituteNothing to disclose Keith C. Ferdinand , MD, FACC, FAHA, FASPC, FNLA
Gerald S. Berenson Endowed Chair in Preventive Cardiology
Professor of Medicine
Tulane University School of MedicineConsulting Fee (e.g., Advisory Board): Amgen, Sanofi, Boehringer Ingelheim, Novartis, Quantum Genomics, Eli Lilly
Darren McGuire, MD, MHSc
Dallas Heart Ball Chair for Research on Heart Disease in Women
University of Texas Southwestern Medical CenterConsulting Fee (e.g., Advisory Board): Lilly USA, Boehringer Ingelheim, Merck & Co, Novo Nordisk, Applied Therapeutics, Metavant, Sanofi, Afimmune, CSL Behring, Bayer, GlaxoSmithKline
Honoraria: Boehringer Ingelheim, Sanofi, Merck & Co, Pfizer, AstraZeneca, Novo Nordisk, Esperion, Lilly USA, Lexicon, CSL Behring
The planners and managers have the following relevant financial relationships with ineligible companies:
Name of Planner Reported Financial Relationship Lindsay Borvansky Nothing to disclose Andrea Funk Nothing to disclose Liddy Knight Nothing to disclose Ashley Cann Nothing to disclose Carole Drexel Nothing to disclose Colleen Hefner Nothing to disclose Caroline Laurendeau Nothing to disclose DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.DISCLAIMER:
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.CONTACT INFORMATION
Accreditation Support:
For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.comTechnical Support:
For any technical issues or issues with your CME Certificate, please contact CardioCareLive at 877-394-1306 or at Support@CardioCareLive.com .
This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with the American Society for Preventive Cardiology (ASPC).ACC Expert Consensus Decision Pathway for Bleeding Management: Applications in Patients on Oral Anticoagulants and Cost Implications
ACKNOWLEDGEMENT
This activity is supported by an educational grant from Alexion Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC, and Merck Sharp & Dohme Corp.DATE OF RELEASE/EXPIRATION
This activity was released on February 9, 2022 and is valid until February 9, 2023. Requests for credit must be made no later than February 9, 2023TARGET AUDIENCE
Cardiologists, internal medicine physicians, primary care physicians, clinical pharmacists, nurse practitioners, physician assistants, nurses, and other clinicians who care for patients with heart failure.STATEMENT OF NEED/PROGRAM OVERVIEW
Anticoagulant therapy is an essential part of managing many cardiovascular diseases. The last decade has seen an expansion of therapies aimed at managing patients with multiple underlying CV manifestations, including the advent of direct oral anticoagulants (DOACs), which changed the standard of care.
Ultimately, the choice of anticoagulant therapy must be considered in the context of underlying CV disease, as well as complex comorbidities (i.e., renal disease, obesity). As the rapid evolution of evidence‐based practice parallels more widespread use of novel oral anticoagulants, it is imperative that clinicians remain up to date on optimal anticoagulation strategies in CV.
Join an esteemed panel of expert clinicians to review the evidence-based recommendations for use of DOACs in patients with cardiovascular disease, including the management of a major and minor bleeding events. The expert panelists will also evaluate the Pharmacoeconomics of current DOAC reversal strategies and the long-term implications for patient morbidity and mortality.EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:- Summarize data around emerging indications for DOACs
- Adopt the 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Direct Oral Anticoagulants
- Evaluate long-term impacts on patient morbidity and mortality and cost effectiveness with specific DOAC reversal agent’s vs usual care with 4F-PCC or aPCC in the critical-care setting
PHYSICIAN ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.PHYSICIAN CREDIT DESIGNATION
Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.ESTIMATED TIME TO COMPLETE
This activity should take approximately 60 minutes to complete.INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.FEE INFORMATION & REFUND/CANCELLATION POLICY
There is no fee for this educational activity.DISCLOSURE OF CONFLICTS OF INTEREST
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Name of Faculty or Presenter Reported Financial Relationship Martha Gulati MD, MS, FACC, FAHA, FASPC, FESC
President-American Society for Preventive Cardiology
Director, Preventive Cardiology
Associate Director, Barbra Streisand Women’s Heart Center
Associate Director, Preventive and Cardiac Rehabilitation Center
Smidt Heart InstituteNothing to disclose Deepak L. Bhatt, MD, MPH
Executive Director of Interventional Cardiovascular Programs
Brigham and Women's Hospital Heart and Vascular Center
Professor of Medicine, Harvard Medical School
Contracted Research: Abbott, Afimmune, Aker Biomarine, Amarin, Amgen, AstraZeneca, Bayer, Beren, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CSL Behring, Eisai, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Lilly, Medtronic, Moderna, MyoKardia, NirvaMed, Novartis, Novo Nordisk, Owkin, Pfizer, PhaseBio, PLx Pharma,Recardio, Regeneron, Roche, Sanofi, Stasys, Synaptic, The Medicines Company, 89Bio Ty Gluckman, MD, MHA,FAAC, FAHA Medical Director Center for Cardiovascular Analytics, Research, and Data Science (CARDS)
Providence Heart Institute
Providence St. Joseph Health
Nothing to disclose
The planners and managers have the following relevant financial relationships with ineligible companies:
Name of Planner or Manager Reported Financial Relationship Lindsay Borvansky Nothing to disclose Andrea Funk Nothing to disclose Liddy Knight Nothing to disclose Ashley Cann Nothing to disclose Carole Drexel Nothing to disclose Eve Wilson Nothing to disclose Caroline Laurendeau Nothing to disclose DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.DISCLAIMER:
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.CONTACT INFORMATION
Accreditation Support:
For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.
Technical Support:
For any technical issues or issues with your CME Certificate, please contact CardioCareLive at 877-394-1306 or at Info@CardioCareLive.com.
This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with the American Society for Preventive Cardiology (ASPC) and the Association of Black Cardiologists.Considerations for Heart Failure Management in the African American Population
ACKNOWLEDGEMENT
This activity is supported by an educational grant from Alexion Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC, and Merck Sharp & Dohme Corp.DATE OF RELEASE/EXPIRATION
This activity was released on January 5, 2022 and is valid until January 5, 2023. Requests for credit must be made no later than January 5, 2023.TARGET AUDIENCE
Cardiologists, internal medicine physicians, primary care physicians, clinical pharmacists, nurse practitioners, physician assistants, nurses, and other clinicians who care for patients with heart failure.STATEMENT OF NEED/PROGRAM OVERVIEW
Anticoagulant therapy is an essential part of managing many cardiovascular diseases. The last decade has seen an expansion of therapies aimed at managing patients with multiple underlying CV manifestations, including the advent of direct oral anticoagulants (DOACs), which changed the standard of care. Ultimately, the choice of anticoagulant therapy must be considered in the context of underlying CV disease, as well as complex comorbidities (i.e., renal disease, obesity). As the rapid evolution of evidence‐based practice parallels more widespread use of novel oral anticoagulants, it is imperative that clinicians remain up to date on optimal anticoagulation strategies in CV. Join an esteemed panel of expert clinicians to review the evidence-based recommendations for use of DOACs in patients with cardiovascular disease, including the management of a major and minor bleeding events. The expert panelists will also evaluate the Pharmacoeconomics of current DOAC reversal strategies and the long-term implications for patient morbidity and mortality.EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:- Identify patient-centric risk factors for development and progression of HF in a racially diverse patient population
- Review best-practice recommendations for pharmacological management of HF, with a focus on African American patients
- Discuss safety, efficacy, and clinical-outcomes data related to new and emerging therapies for HF
PHYSICIAN ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.PHYSICIAN CREDIT DESIGNATION
Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.ESTIMATED TIME TO COMPLETE
This activity should take approximately 60 minutes to complete.INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.FEE INFORMATION & REFUND/CANCELLATION POLICY
There is no fee for this educational activity.DISCLOSURE OF CONFLICTS OF INTEREST
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias. All relevant financial relationships have been mitigated. The faculty have the following relevant financial relationships with ineligible companies:
The planners and managers have the following relevant financial relationships with ineligible companies:Name of Faculty or Presenter Reported Financial Relationship Martha Gulati MD, MS, FACC, FAHA, FASPC, FESC
President-American Society for Preventive Cardiology
Director, Preventive Cardiology
Associate Director, Barbra Streisand Women’s Heart Center
Associate Director, Preventive and Cardiac Rehabilitation Center
Smidt Heart InstituteNothing to disclose Nasrien Ibrahim Assistant Program Director, Cardiology Fellowship Director, Heart Failure Research Inova Heart and Vascular Institute Consulting Fee (e.g., Advisory Board): Cytokinetics Honoraria: Novartis, Medtronic, Roche, Cytokinetics Clyde Yancy Vice-Dean of Diversity & Inclusion and Professor and Chief of the Division of Cardiology at Northwestern University Feinberg School of Medicine Nothing to disclose Name of Planner or Manager Reported Financial Relationship Lindsay Borvansky Nothing to disclose Andrea Funk Nothing to disclose Liddy Knight Nothing to disclose Ashley Cann Nothing to disclose Kim Rodriguez Nothing to disclose Carole Drexel Nothing to disclose Eve Wilson Nothing to disclose Caroline Laurendeau Nothing to disclose DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.DISCLAIMER:
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.CONTACT INFORMATION
Accreditation Support: For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com. Technical Support: For any technical issues or issues with your CME Certificate, please contact CardioCareLive at 877-394-1306 or at Info@CardioCareLive.com.
